Introduction: Inflammatory bowel disease (IBD) affects approximately 7 million people worldwide. In the U.S. alone, per the CDC, 1.3% of adults, which is approximately 3,000,000 people, are diagnosed with inflammatory bowel disease-either, Crohn’s disease, or ulcerative colitis. The estimated cost of treatment can be close to $23,000 annually, with treatment regimens comprising biologic agents and anti-inflammatory therapies. Probiotics have recently gathered interest as a low-cost additional therapy option that, in addition to the current regimen of IBD management, allows for reductions in rates of IBD flare-ups by significantly reducing the number of emergency room visits and avoiding the need to constantly escalate treatment by addition of biologic agents in achieving remission. The Analysis Go al: Our research project aimed to see if there was a significant difference in the addition of probiotics to standard therapy in inflammatory bowel disease by comparing existing research studies and trials. We analyzed RCTs published in PubMed to assess the efficacy and safety of probiotics in patients with IBD in preventing frequent disease flare-ups and reducing the cost of care. Research Methods: We did a comparative analysis of available RCTs using a PubMed search and included studies that researched the addition of probiotic strains in patients with IBD (ulcerative colitis and Crohn’s disease). After reviewing the inclusion and exclusion criteria, the trials selected for analysis were reviewed by two independent reviewers. Results: We analyzed 21 RCTs, and 16 RCTs (76.2%) showed that probiotics are an effective therapy for IBD, inducing remission and reducing flare-up rates in patients on a standard treatment regimen. Conclusion: Probiotics given in combination with standard therapy in IBD are effective in decreasing disease activity rates and reducing remission rates. No significant adverse reactions to probiotics were noticed.
Jakubczyk, D., Leszczyńska, K. and Górska, S. (2020) The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review. N u trients , 12, Article 1973. https://doi.org/10.3390/nu12071973
Ng, S.C. (2015) Emerging Leadership Lecture: Inflammatory Bowel Disease in Asia: Emergence of a “Western” Disease. The Journal of Gastroenterology and Hepatol o gy , 30, 440-445. https://doi.org/10.1111/jgh.12859
Chou, J.W., Lai, H.C., Chang, C.H., Cheng, K.S., Feng, C.L. and Chen, T.W. (2019) Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan Region. Gastroenterology Research and Practice , 2019, Article 4175923. https://doi.org/10.1155/2019/4175923
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T. and Zhang, C. (2019) Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens , 8, Article 126. https://doi.org/10.3390/pathogens8030126
Foster, A. and Jacobson, K. (2013) Changing Incidence of Inflammatory Bowel Disease: Environmental Influences and Lessons Learned from the South Asian Population. Front iers in Pediatr ics, 1, Article 34. https://doi.org/10.3389/fped.2013.00034
Sekirov, I., Russell, S.L., Antunes, L.C.M. and Finlay, B.B. (2010) Gut Microbiota in Health and Disease. Physiol ogical Rev iews , 90, 859-904. https://doi.org/10.1152/physrev.00045.2009
De Souza, H.S. and Fiocchi, C. (2016) Immunopathogenesis of IBD: Current State of the Art. Nature Reviews Gastroenterology & Hepatology , 13, 13-27. https://doi.org/10.1038/nrgastro.2015.186
Rosen, C.E. and Palm, N.W. (2018) Navigating the Microbiota Seas: Triangulation Finds a Way Forward. Cell Host and Microbe , 23, 1-3. https://doi.org/10.1016/j.chom.2017.12.015
Gkouskou, K., Deligianni, C., Tsatsanis, C. and Eliopoulos, A.G. (2014) The Gut Microbiota in Mouse Models of Inflammatory Bowel Disease. Frontiers in Cellular and Infection Microbiology , 4, Article 28. https://doi.org/10.3389/fcimb.2014.00028
Damaskos, D. and Kolios, G. (2008) Probiotics, and Prebiotics in Inflammatory Bowel Disease: Microflora ‘On the Scope’. B ritish Journal of Clinical Pharmacology , 65, 453-467. https://doi.org/10.1111/j.1365-2125.2008.03096.x
Fan, H., Du, J., Liu, X., Zheng, W.W., Zhuang, Z.H., Wang, C.D. and Gao, R. (2019) Effects of Pentasa-Combined Probiotics on the Microflora Structure and Prognosis of Patients with Inflammatory Bowel Disease. Turkish Journal of Gastroenterology , 30, 680-685. https://doi.org/10.5152/tjg.2019.18426
Bibiloni, R., Fedorak, R.N., Tannock, G.W., Madsen, K.L., Gionchetti, P., Campieri, M., De Simone, C. and Sartor, R.B. (2005) VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. American Journal of Gastroe n terology , 100, 1539-1546. https://doi.org/10.1111/j.1572-0241.2005.41794.x
Bourreille, A., Cadiot, G., Le Dreau, G., Laharie, D., Beaugerie, L., Dupas, J.L., Marteau, P., Rampal, P., Moyse, D., Saleh, A., Le Guern, M.E. and Galmiche, J.P. (2013) FLORABEST Study Group. Saccharomyces Boulardii Does Not Prevent Relapse of Crohn’s Disease. Clinical Gastroenterology and Hepatology , 11, 982-987. https://doi.org/10.1016/j.cgh.2013.02.021
Agraib, L.M., Yamani, M.I., Tayyem, R., Abu-Sneineh, A.T. and Rayyan, Y.M. (2022) Probiotic Supplementation Induces Remission and Changes in the Immunoglobulins and Inflammatory Response in Active Ulcerative Colitis Patients: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study. Clin ical Nutr ition ESPEN , 51, 83-91. https://doi.org/10.1016/j.clnesp.2022.08.020
Palumbo, V.D., Romeo, M., Marino Gammazza, A., Carini, F., Damiani, P., Damiano, G., Buscemi, S., Lo Monte, A.I., Gerges-Geagea, A., Jurjus, A. and Tomasello, G. (2016) The Long-Term Effects of Probiotics in the Therapy of Ulcerative Colitis: A Clinical Study. Biomedical Papers of the Medical Faculty of the University Palacky , Olomouc , Czech Republic , 160, 372-377. https://doi.org/10.5507/bp.2016.044
Prantera, C. and Scribano, M.L. (2002) Probiotics and Crohn’s Disease. Dig estive and Liver Dis ease , 34, 66-67. https://doi.org/10.1016/S1590-8658(02)80168-2
Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, P.A. (2000) Saccharomyces Bo u lardii in Maintenance Treatment of Crohn’s Disease. Digestive Diseases and Sciences , 45, 1462-1464. https://doi.org/10.1023/A:1005588911207
Schultz, M., Timmer, A., Herfarth, H.H., Sartor, R.B., Vanderhoof, J.A. and Rath, H.C. (2004) Lactobacillus GG in Inducing and Maintaining Remission of Crohn’s disease. BMC Gastroenterology , 4, Article 5. https://doi.org/10.1186/1471-230X-4-5
Huang, M., Chen, Z.Q., Lang, C., Chen, J., Yang, B., Xue, L. and Zhang, Y. (2018) Efficacy of Mesalazine in Combination with Bifid Triple Viable Capsules on Ulcerative Colitis and the Resultant Effect on the Inflammatory Factors. Pakistan Journal of Pharmaceutical Sciences , 31, 2891-2895.
Yoshimatsu, Y., Yamada, A., Furukawa, R., Sono, K., Osamura, A., Nakamura, K., Aoki, H., Tsuda, Y., Hosoe, N., Takada, N. and Suzuki, Y. (2015) Effectiveness of Probiotic Therapy for the Prevention of Relapse in Patients with Inactive Ulcerative Colitis. World Journal of Gastroenterology , 21, 5985-5994. https://doi.org/10.3748/wjg.v21.i19.5985
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G.M., Forti, G., Morini, S., Hassan, C., Pistoia, M.A., Modeo, M.E., Rodino’, S., D’Amico, T., Sebkova, L., Sacca’, N., Di Giulio, E., Luzza, F., Imeneo, M., Larussa, T., Di Rosa, S., Annese, V., Danese, S. and Gasbarrini, A. (2010) Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis with the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Con-trolled Study. The American Journal of Gastroenterology , 105, 2218-2227. https://doi.org/10.1038/ajg.2010.218
Kruis, W., Fric, P., Pokrotnieks, J., Lukás, M., Fixa, B., Kascák, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C. and Schulze, J. (2004) Maintaining Remission of Ulcerative Colitis with the Probiotic Escherichia coli Nissle 1917 Is as Effective as with Standard Mesalazine. Gut , 53, 1617-1623. https://doi.org/10.1136/gut.2003.037747
Zocco, M.A., Dal Verme, L.Z., Cremonini, F., Piscaglia, A.C., Nista, E.C., Candelli, M., Novi, M., Rigante, D., Cazzato, I.A., Ojetti, V., Armuzzi, A., Gasbarrini, G. and Gasbarrini, A. (2006) Efficacy of Lactobacillus GG in Maintaining Remission of Ulcerative Colitis. Alimentary Pharmacology & Therapeutics , 23, 1567-1574. https://doi.org/10.1111/j.1365-2036.2006.02927.x
Cui, H.H., Chen, C.L., Wang, J.D., Yang, Y.J., Cun, Y., Wu, J.B., Liu, Y.H., Dan, H.L., Jian, Y.T. and Chen, X.Q. (2004) Effects of Probiotic on Intestinal Mucosa of Patients with Ulcerative Colitis. World Journal of Gastroenterology , 10, 1521-1525. https://doi.org/10.3748/wjg.v10.i10.1521
Sood, A., Midha, V., Makharia, G.K., Ahuja, V., Singal, D., Goswami, P. and Tandon, R.K. (2009) The Probiotic Preparation, VSL#3 Induces Remission in Patients with Mild-to-Moderately Active Ulcerative Colitis. Clinical Gastroenterology and Hep a tology , 7, 1202-1209. https://doi.org/10.1016/j.cgh.2009.07.016
Petersen, A.M, Mirsepasi, H., Halkjær, S.I., Mortensen, E.M., Nordgaard-Lassen, I. and Krogfelt, K.A. (2014) Ciprofloxacin and Probiotic Escherichia c oli Nissle Add-on Treatment in Active Ulcerative Colitis: A Double-Blind, Randomized Placebo-Controlled Clinical Trial. Journal of Crohn ’ s & Colitis , 8, 1498-1505. https://doi.org/10.1016/j.crohns.2014.06.001
Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M. and Axon, A.T. (1999) Non-Pathogenic Escherichia c oli versus Mesalazine for the Treatment of Ulcerative Colitis: A Randomized Trial. The Lancet , 354, 635-639. https://doi.org/10.1016/S0140-6736(98)06343-0
Wildt, S., Nordgaard, I., Hansen, U., Brockmann, E. and Rumessen, J.J. (2011) A Randomized, Double-Blind Placebo-Controlled Trial with Lactobacillus a cidophilus La-5 and Bifidobacterium a nimalis Subsp. Lactis BB-12 for Maintenance of Remission in Ulcerative Colitis. Journal of Crohn ’ s & Colitis , 5, 115-121. https://doi.org/10.1016/j.crohns.2010.11.004
Tamaki, H., Nakase, H., Inoue, S., Kawanami, C., Itani, T., Ohana, M., Kusaka, T., Uose, S., Hisatsune, H., Tojo, M., Noda, T., Arasawa, S., Izuta, M., Kubo, A., Ogawa, C., Matsunaka, T. and Shibatouge, M. (2016) Efficacy of Probiotic Treatment with Bifidobacterium l ongum 536 for Induction of Remission in Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial. Dige s tive Endoscopy , 28, 67-74. https://doi.org/10.1111/den.12553
Kruis, W., Schütz, E., Fric, P., Fixa, B., Judmaier, G. and Stolte, M. (1997) Double-Blind Comparison of an Oral Escherichia Coli Preparation and Mesalazine in Maintaining Remission of Ulcerative Colitis. Alimentary Pharmacology & Th e rapeutics , 11, 853-858. https://doi.org/10.1046/j.1365-2036.1997.00225.x
Tursi, A., Brandimarte, G., Giorgetti, G.M., Forti, G., Modeo, M.E. and Gigliobianco, A. (2004) Low-Dose Balsalazide Plus a High-Potency Probiotic Preparation Is More Effective than Balsalazide Alone or Mesalazine in the Treatment of Acute Mild-to-Moderate Ulcerative Colitis. Med ical Sci ence Monit or , 10, 1126-1131.
Kaplan, G.G. (2015) The Global Burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology , 12, 720-727. https://doi.org/10.1038/nrgastro.2015.150
Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y. and Andoh, A. (2018) Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease. Clinical Journal of Gastroenterology , 11, 1-10. https://doi.org/10.1007/s12328-017-0813-5
Katz, J. (2006) The Role of Probiotics in IBD. Gastroenterology & Hepatology ( NY ), 2, 16-18.
Rath, H.C., Herfarth, H.H., Ikeda, J.S., et al . (1996) Normal Luminal Bacteria, Especially Bacteroides Species, Mediate Chronic Colitis, Gastritis, and Arthritis in HLA-B27/Human β 2 Microglobulin Transgenic Mice. The Journal of Clinical I n vestigation , 98, 945-953.
Campieri, M. and Gionchetti, P. (1999) Probiotics in Inflammatory Bowel Disease: New Insights to Pathogenesis or a Possible Therapeutic Alternative. Gastroentero l ogy , 116, 1246-1249. https://doi.org/10.1016/S0016-5085(99)70029-6
Linskens, R.K., Huijsdens, X.W., Savelkoul, P.H., Vandenbroucke-Grauls, C.M. and Meuwissen, S.G. (2001) The Bacterial Flora in Inflammatory Bowel Disease: Current Insights in Pathogenesis and the Influence of Antibiotics and Probiotics. Sca n dinavian Journal of Gastroenterology , 36, 29-40. https://doi.org/10.1080/003655201753265082
Schultz, M., Scholmerich, J. and Rath, H.C. (2003) Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases. Digestive Diseases , 21, 105-128. https://doi.org/10.1159/000073243
Yan, F. and Polk, D.B. (2002) Probiotic Bacterium Prevents Cytokine—In Intestinal Epithelial Cells. J ournal of Biol ogical Chem istry , 277, 50959-50965. https://doi.org/10.1074/jbc.M207050200
Ulisse, S., Gionchetti, P., D’Alo, S., et al . (2001) Expression of Cytokines, Inducible Nitric Oxide Synthase, and Matrix Metalloproteinases in Pouchitis: Effects of Probiotic Treatment. The American Journal of Gastroenterology , 96, 2691-2699.
Furrie, E., Macfarlane, S., Kennedy, A., et al . (2005) Synbiotic Therapy ( Bifidobact e rium l ongum /Synergy 1) Initiates Resolution of Inflammation in Patients with Active Ulcerative Colitis: A Randomised Controlled Pilot Trial. Gut , 54, 242-249. https://doi.org/10.1136/gut.2004.044834
Schultz, M., Linde, H.J., Lehn, N., et al . (2003) Immunomodulatory Consequences of Oral Administration of Lactobacillus r hamnosus Strain GG in Healthy Volunteers. Journal of Dairy Science , 70, 165-173. https://doi.org/10.1017/S0022029903006034
Schultz, M., Veltkamp, C., Dieleman, L.A., et al . (2002) Lactobacillus p lantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice. Inflammatory Bowel Diseases , 8, 71-80. https://doi.org/10.1097/00054725-200203000-00001
Dieleman, L.A., Goerres, M.S., Arends, A., et al . (2003) Lactobacillus GG Prevents Recurrence of Colitis in HLA-B27 Transgenic Rats after Antibiotic Treatment. Gut , 52, 370-376. https://doi.org/10.1136/gut.52.3.370